Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma

(2015) Nicholas C. Wolff et al.   Oncotarget

Lack of a Functional VHL Gene Product Sensitizes Renal Cell Carcinoma Cells to the Apoptotic Effects of the Protein Synthesis Inhibitor Verrucarin A

(2015) Girma M. Woldemichael et al.   NEOPLASIA

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Adjuvant Therapy for Renal Cell Carcinoma

(2014) Alvaro Pinto   Clinical Genitourinary Cancer

Antitumoral effect of a selective Rho-kinase inhibitor Y-27632 against Ehrlich ascites carcinoma in mice

(2014) Derya Isler et al.   Pharmacological Reports

Rho-kinase: regulation, (dys)function, and inhibition

(2013) Ehsan Amin et al.   BIOLOGICAL CHEMISTRY

The Apoptosis Repressor with a CARD Domain (ARC) Gene Is a Direct Hypoxia-Inducible Factor 1 Target Gene and Promotes Survival and Proliferation of VHL-Deficient Renal Cancer Cells

(2013) O. V. Razorenova et al.   MOLECULAR AND CELLULAR BIOLOGY

ROCK has a crucial role in regulating prostate tumor growth through interaction with c-Myc

(2013) C Zhang et al.   ONCOGENE

Hypoxia-inducible factors mediate coordinated RhoA-ROCK1 expression and signaling in breast cancer cells

(2013) D. M. Gilkes et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Distinct roles for ROCK1 and ROCK2 in the regulation of cell detachment

(2013) Jianjian Shi et al.   Cell Death & Disease

Axitinib for the Management of Metastatic Renal Cell Carcinoma

(2013) Bernard Escudier et al.   Drugs in research & development

RKI-1447 Is a Potent Inhibitor of the Rho-Associated ROCK Kinases with Anti-Invasive and Antitumor Activities in Breast Cancer

(2012) R. A. Patel et al.   CANCER RESEARCH

Regulation of autophagosome formation by Rho kinase

(2012) Andrzej Mleczak et al.   CELLULAR SIGNALLING

State of the Science: An Update on Renal Cell Carcinoma

(2012) E. Jonasch et al.   MOLECULAR CANCER RESEARCH

The Roles of VHL-Dependent Ubiquitination in Signaling and Cancer

(2012) Qing Zhang et al.   Frontiers in Oncology

ROCK1 as a potential therapeutic target in osteosarcoma

(2011) Xianzhe Liu et al.   JOURNAL OF ORTHOPAEDIC RESEARCH

Harnessing synthetic lethal interactions in anticancer drug discovery

(2011) Denise A. Chan et al.   NATURE REVIEWS DRUG DISCOVERY

VHLloss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKCδ-driven migration

(2011) Olga V. Razorenova et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality

(2011) D. A. Chan et al.   Science Translational Medicine

Phase 3 trial of everolimus for metastatic renal cell carcinoma

(2010) Robert J. Motzer et al.   CANCER

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

(2010) Cora N. Sternberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Activating ROCK1 somatic mutations in human cancer

(2010) P A Lochhead et al.   ONCOGENE

Inhibition of Rho-Associated Kinase Signaling Prevents Breast Cancer Metastasis to Human Bone

(2009) S. Liu et al.   CANCER RESEARCH

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

(2009) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Resistance to targeted therapy in renal-cell carcinoma

(2009) Brian I Rini et al.   LANCET ONCOLOGY

VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy

(2009) C. Lance Cowey et al.   Current Oncology Reports

Possible role of the RhoC/ROCK pathway in progression of clear cell renal cell carcinoma

(2008) Hideyuki ABE et al.   BIOMEDICAL RESEARCH-TOKYO

Antiepileptic effects of two Rho-kinase inhibitors, Y-27632 and fasudil, in mice

(2008) S Y İnan et al.   BRITISH JOURNAL OF PHARMACOLOGY

HIF-α Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal Carcinoma

(2008) John D. Gordan et al.   CANCER CELL

A Molecule Targeting VHL-Deficient Renal Cell Carcinoma that Induces Autophagy

(2008) Sandra Turcotte et al.   CANCER CELL

The VHL tumor suppressor and HIF: insights from genetic studies in mice

(2008) P P Kapitsinou et al.   CELL DEATH AND DIFFERENTIATION

Fasudil-induced hypoxia-inducible factor-1α degradation disrupts a hypoxia-driven vascular endothelial growth factor autocrine mechanism in endothelial cells

(2008) Keiko Takata et al.   MOLECULAR CANCER THERAPEUTICS

Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen

(2008) A. Bommi-Reddy et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA